MDSCs in Breast Cancer: an Important Enabler of Tumor Progression and an Emerging Therapeutic Target

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Jul 19

PMID 37465670

Authors

Haoyu Liu

Zhicheng Wang

Yuntao Zhou

Yanming Yang

Affiliations

Soon will be listed here.

Abstract

Women worldwide are more likely to develop breast cancer (BC) than any other type of cancer. The treatment of BC depends on the subtype and stage of the cancer, such as surgery, radiotherapy, chemotherapy, and immunotherapy. Although significant progress has been made in recent years, advanced or metastatic BC presents a poor prognosis, due to drug resistance and recurrences. During embryonic development, myeloid-derived suppressor cells (MDSCs) develop that suppress the immune system. By inhibiting anti-immune effects and promoting non-immune mechanisms such as tumor cell stemness, epithelial-mesenchymal transformation (EMT) and angiogenesis, MDSCs effectively promote tumor growth and metastasis. In various BC models, peripheral tissues, and tumor microenvironments (TME), MDSCs have been found to amplification. Clinical progression or poor prognosis are strongly associated with increased MDSCs. In this review, we describe the activation, recruitment, and differentiation of MDSCs production in BC, the involvement of MDSCs in BC progression, and the clinical characteristics of MDSCs as a potential BC therapy target.

Citing Articles

Inhibiting CXCR4 reduces immunosuppressive effects of myeloid cells in breast cancer immunotherapy.

Ciavattone N, Bevoor A, Farfel A, Rehman A, Ho K, Rock E Sci Rep. 2025; 15(1):5204.

PMID: 39939722 PMC: 11822021. DOI: 10.1038/s41598-025-89882-5.

Targeting breast tumor extracellular matrix and stroma utilizing nanoparticles.

Muhammad F, Altalbawy F, Mandaliya V, Saraswat S, Rekha M, Aulakh D Clin Transl Oncol. 2024; .

PMID: 39692807 DOI: 10.1007/s12094-024-03793-x.

Delineating the nexus between gut-intratumoral microbiome and osteo-immune system in bone metastases.

Kapoor S, Gupta M, Sapra L, Kaur T, Srivastava R Bone Rep. 2024; 23:101809.

PMID: 39497943 PMC: 11532283. DOI: 10.1016/j.bonr.2024.101809.

Resting natural killer cells promote the progress of colon cancer liver metastasis by elevating tumor-derived stem cell factor.

Mao C, Chen Y, Xing D, Zhang T, Lin Y, Long C Elife. 2024; 13.

PMID: 39387546 PMC: 11466454. DOI: 10.7554/eLife.97201.

Enhancing cancer immunotherapy: Nanotechnology-mediated immunotherapy overcoming immunosuppression.

Chen Y, Zhou Q, Jia Z, Cheng N, Zhang S, Chen W Acta Pharm Sin B. 2024; 14(9):3834-3854.

PMID: 39309502 PMC: 11413684. DOI: 10.1016/j.apsb.2024.05.032.

References

Gao W, Wen H, Liang L, Dong X, Du R, Zhou W . IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer. Theranostics. 2021; 11(6):2564-2580. PMC: 7806486. DOI: 10.7150/thno.45280. View

Salemme V, Centonze G, Cavallo F, Defilippi P, Conti L . The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. Front Oncol. 2021; 11:610303. PMC: 7991834. DOI: 10.3389/fonc.2021.610303. View

Hu S, Ma J, Su C, Chen Y, Shu Y, Qi Z . Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis. Acta Biomater. 2021; 135:567-581. DOI: 10.1016/j.actbio.2021.09.003. View

Kun Z, Xin G, Tao W, Chenglong Z, Dongsheng W, Liang T . Tumor derived EDIL3 modulates the expansion and osteoclastogenesis of myeloid derived suppressor cells in murine breast cancer model. J Bone Oncol. 2019; 16:100238. PMC: 6512748. DOI: 10.1016/j.jbo.2019.100238. View

Zhang R, Wan Y, Lv H, Li F, Lee C . DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy. J Mater Chem B. 2021; 9(36):7544-7556. DOI: 10.1039/d1tb00269d. View

Sun R, Luo H, Su J, Di S, Zhou M, Shi B . Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice. Mol Ther. 2020; 29(1):60-74. PMC: 7791086. DOI: 10.1016/j.ymthe.2020.09.034. View

Lu Z, Zou J, Li S, Topper M, Tao Y, Zhang H . Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. 2020; 579(7798):284-290. PMC: 8765085. DOI: 10.1038/s41586-020-2054-x. View

Zheng Y, Wang N, Wang S, Yang B, Situ H, Zhong L . XIAOPI formula inhibits the pre-metastatic niche formation in breast cancer via suppressing TAMs/CXCL1 signaling. Cell Commun Signal. 2020; 18(1):48. PMC: 7098160. DOI: 10.1186/s12964-020-0520-6. View

Tian S, Song X, Wang Y, Wang X, Mou Y, Chen Q . Chinese herbal medicine Baoyuan Jiedu decoction inhibits the accumulation of myeloid derived suppressor cells in pre-metastatic niche of lung via TGF-β/CCL9 pathway. Biomed Pharmacother. 2020; 129:110380. DOI: 10.1016/j.biopha.2020.110380. View

10.

Tanaka T, Kajiwara T, Torigoe T, Okamoto Y, Sato N, Tamura Y . Cancer-associated oxidoreductase ERO1-α drives the production of tumor-promoting myeloid-derived suppressor cells via oxidative protein folding. J Immunol. 2015; 194(4):2004-10. DOI: 10.4049/jimmunol.1402538. View

11.

Bauer R, Udonta F, Wroblewski M, Ben-Batalla I, Santos I, Taverna F . Blockade of Myeloid-Derived Suppressor Cell Expansion with All- Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy. Cancer Res. 2018; 78(12):3220-3232. DOI: 10.1158/0008-5472.CAN-17-3415. View

12.

Alshetaiwi H, Pervolarakis N, McIntyre L, Ma D, Nguyen Q, Rath J . Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol. 2020; 5(44). PMC: 7219211. DOI: 10.1126/sciimmunol.aay6017. View

13.

Uribesalgo I, Hoffmann D, Zhang Y, Kavirayani A, Lazovic J, Berta J . Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy. EMBO Mol Med. 2019; 11(8):e9266. PMC: 6685079. DOI: 10.15252/emmm.201809266. View

14.

Gu P, Sun M, Li L, Yang Y, Jiang Z, Ge Y . Breast Tumor-Derived Exosomal MicroRNA-200b-3p Promotes Specific Organ Metastasis Through Regulating CCL2 Expression in Lung Epithelial Cells. Front Cell Dev Biol. 2021; 9:657158. PMC: 8264457. DOI: 10.3389/fcell.2021.657158. View

15.

Gupta N, Gaikwad S, Kaushik I, Wright S, Markiewski M, Srivastava S . Atovaquone Suppresses Triple-Negative Breast Tumor Growth by Reducing Immune-Suppressive Cells. Int J Mol Sci. 2021; 22(10). PMC: 8152242. DOI: 10.3390/ijms22105150. View

16.

Kodumudi K, Woan K, Gilvary D, Sahakian E, Wei S, Djeu J . A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010; 16(18):4583-94. PMC: 3874864. DOI: 10.1158/1078-0432.CCR-10-0733. View

17.

Liu Y, Tiruthani K, Wang M, Zhou X, Qiu N, Xiong Y . Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer. Nanoscale Horiz. 2021; 6(4):319-329. PMC: 8638658. DOI: 10.1039/d0nh00588f. View

18.

Jiang M, Zhang W, Zhang R, Liu P, Ye Y, Yu W . Cancer exosome-derived miR-9 and miR-181a promote the development of early-stage MDSCs via interfering with SOCS3 and PIAS3 respectively in breast cancer. Oncogene. 2020; 39(24):4681-4694. DOI: 10.1038/s41388-020-1322-4. View

19.

Kumar S, Wilkes D, Samuel N, Blanco M, Nayak A, Alicea-Torres K . ΔNp63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer. J Clin Invest. 2018; 128(11):5095-5109. PMC: 6205409. DOI: 10.1172/JCI99673. View

20.

Cassetta L, Baekkevold E, Brandau S, Bujko A, Cassatella M, Dorhoi A . Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates. Cancer Immunol Immunother. 2019; 68(4):687-697. PMC: 6447515. DOI: 10.1007/s00262-019-02302-2. View